FDA fast-tracks psychedelic drug research following Trump executive order
The Food and Drug Administration announced on Friday a series of actions intended to accelerate the use of psychedelic treatments for serious mental illness, including fast-tracking research for approval to bring new drugs to market.
The move from the FDA comes just six days after President Donald Trump signed an executive order on Saturday directing […]
- U.S. FDA plans ultra-fast review of three psychedelic drugs following Trump directive CTV News —
- US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive South China Morning Post —
- FDA grants quick review for 3 psychedelic drug trials NBC News —
- FDA fast-tracks psychedelic drug research following Trump executive order CNBC —
- FDA plans fast review of 3 psychedelic drugs following Trump directive Boston Globe —